日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Pembrolizumab in Combination with Binimetinib in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

帕博利珠单抗联合比美替尼治疗不可切除的局部晚期或转移性三阴性乳腺癌患者

Chumsri, Saranya; Larson, Joseph J; Liu, Emily; Tenner, Kathleen S; Adams, Daniel; Weidner, Morgan T; Arnold, Amanda N; Haley, Dana L; Advani, Pooja; Sideras, Kostandinos; Moreno-Aspitia, Alvaro; Thompson, E Aubrey; Perez, Edith A; Knutson, Keith L

Long-term cellular and humoral responses to SARS-CoV-2 vaccinations in patients with solid malignancies undergoing chemotherapy

接受化疗的实体恶性肿瘤患者接种SARS-CoV-2疫苗后的长期细胞和体液免疫反应

Liu, Andrew; Necela, Brian; Li, Zhuo; Cogen, Davitte; Wieczorek, Mikolaj A; Mummareddy, Ashita; Acampora, Marites; Reynolds, Gina A; Advani, Pooja P; Moreno-Aspitia, Alvaro; Swift, Melanie D; Virk, Abinash; Bharucha, Adil E; Marquez, Christopher P; Patel, Tushar C; Knutson, Keith L; Chumsri, Saranya

Clinical Treatment Score Post-5 Years (CTS5) and Late Recurrence Risk in Hormone Receptor-Positive, HER2-Positive Breast Cancer

临床治疗评分5年后(CTS5)与激素受体阳性、HER2阳性乳腺癌的晚期复发风险

Chumsri, Saranya; Pai, Tanmayi; Ma, Yaohua; Li, Zhuo; Gil, Angelica; Moreno-Aspitia, Alvaro; Colon-Otero, Gerardo; Pogue-Geile, Katherine L; Rasgoti, Priya; Paik, Soonmyung; Perez, Edith A; Thompson, E Aubrey

Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]

ALTTO 试验的最终分析:曲妥珠单抗序贯或联合拉帕替尼治疗 HER2 阳性早期乳腺癌患者 [BIG 2-06/NCCTG N063D (Alliance)]

de Azambuja, E; Piccart-Gebhart, M; Fielding, S; Townend, J; Hillman, D W; Colleoni, M; Roylance, R; Kelly, C M; Lombard, J; El-Abed, S; Choudhury, A; Korde, L; Vicente, M; Chumsri, S; Rodeheffer, R; Ellard, S L; Wolff, A C; Holtschmidt, J; Lang, I; Untch, M; Boyle, F; Xu, B; Werutsky, G; Tujakowski, J; Huang, C-S; Baruch, N B; Bliss, J; Ferro, A; Gralow, J; Kim, S-B; Kroep, J R; Krop, I; Kuemmel, S; McConnell, R; Moscetti, L; Knop, A S; van Duijnhoven, F; Gomez, H; Cameron, D; Di Cosimo, S; Gelber, R D; Moreno-Aspitia, A

The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study

红细胞生成刺激剂联合辅助抗HER2治疗对早期乳腺癌患者预后的影响:ALTTO研究的亚组分析

Martins-Branco, Diogo; Kassapian, Marie; Debien, Véronique; Caparica, Rafael; Eiger, Daniel; Dafni, Urania; Andriakopoulou, Charitini; El-Abed, Sarra; Ellard, Susan L; Izquierdo, Miguel; Vicente, Malou; Chumsri, Saranya; Piccart-Gebhart, Martine; Moreno-Aspitia, Alvaro; Knop, Ann Søegaard; Lombard, Janine; de Azambuja, Evandro

Circulating microRNAs and therapy-associated cardiac events in HER2-positive breast cancer patients: an exploratory analysis from NeoALTTO

循环microRNA与HER2阳性乳腺癌患者治疗相关心脏事件:来自NeoALTTO的探索性分析

Pizzamiglio, S; Ciniselli, C M; de Azambuja, E; Agbor-Tarh, D; Moreno-Aspitia, A; Suter, T M; Trama, A; De Santis, M C; De Cecco, L; Iorio, M V; Silvestri, M; Pruneri, G; Verderio, P; Di Cosimo, S

Integration of multiomics data shows down regulation of mismatch repair and tubulin pathways in triple-negative chemotherapy-resistant breast tumors

多组学数据整合显示,三阴性化疗耐药性乳腺肿瘤中错配修复和微管蛋白通路下调

Tang, Xiaojia; Thompson, Kevin J; Kalari, Krishna R; Sinnwell, Jason P; Suman, Vera J; Vedell, Peter T; McLaughlin, Sarah A; Northfelt, Donald W; Aspitia, Alvaro Moreno; Gray, Richard J; Carter, Jodi M; Weinshilboum, Richard; Wang, Liewei; Boughey, Judy C; Goetz, Matthew P

Impact of the COVID-19 pandemic on breast, colorectal, lung, and prostate cancer stage at diagnosis according to race

根据种族划分,COVID-19 大流行对乳腺癌、结直肠癌、肺癌和前列腺癌诊断分期的影响

Berrian, Jennifer; Liu, Ying; Ezenwajiaku, Nkiruka; Moreno-Aspitia, Alvaro; Holton, Sara J; Toriola, Adetunji T; Colditz, Graham A; Housten, Ashley J; Hall, Lannis; Fiala, Mark A; Ademuyiwa, Foluso O

Operational Metrics for the ELAINE 2 Study Combining a Traditional Approach With a Just-in-TIME Model

ELAINE 2 研究的运营指标:结合传统方法和即时模式

Blau, Sibel; Peguero, Julio Antonio; Moore, Halle C F; Anderson, Ian Churchill; Barve, Minal A; Cherian, Mathew Amprayil; Elkhanany, Ahmed; O'Sullivan, Ciara Catherine; Moreno-Aspitia, Alvaro; Plourde, Paul; Gleich, Lyon L; Riesen, Kendra; Ezzati, Ross; Degele, Meghan; Shulman, Megan; Stempf, Stephanie Dobson; Sachse, Laura; Iyer, Amrita A; Damodaran, Senthil; Cooney, Matthew M

Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials

NCCTG(Alliance)N9831 和 NeoALTTO 试验中 HER2 阳性乳腺癌的适应性免疫特征

Chumsri, Saranya; Li, Zhuo; Serie, Daniel J; Norton, Nadine; Mashadi-Hossein, Afshin; Tenner, Kathleen; Brauer, Heather Ann; Warren, Sarah; Danaher, Patrick; Colon-Otero, Gerardo; Partridge, Ann H; Carey, Lisa A; Hilbers, Florentine; Van Dooren, Veerle; Holmes, Eileen; Di Cosimo, Serena; Werner, Olena; Huober, Jens Bodo; Dueck, Amylou C; Sotiriou, Christos; Saura, Cristina; Moreno-Aspitia, Alvaro; Knutson, Keith L; Perez, Edith A; Thompson, E Aubrey